​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen (BIIB) stock forecast, based on 43 Wall Street analysts, predicts a 12-month average price target of $240.40, with a high of $315.00 and a low of $160.00. This represents a 102.68% increase from the last price of $118.61.

$100 $150 $200 $250 $300 $350 High: $315 Avg: $240.4 Low: $160 Last Closed Price: $118.61

BIIB Stock Rating

Biogen stock's rating consensus is Buy, based on 43 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (62.79%), 16 Hold (37.21%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 43 16 27 0 Strong Sell Sell Hold Buy Strong Buy

BIIB Price Target Upside V Benchmarks

TypeNameUpside
StockBiogen102.68%
SectorHealthcare Stocks 35.94%
IndustryDrug Manufacturers - General Stocks37.39%

Price Target Trends

1M3M12M
# Anlaysts-428
Avg Price Target-$215.00$266.71
Last Closing Price$118.61$118.61$118.61
Upside/Downside-81.27%124.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2561317--36
Mar, 2561317--36
Feb, 2551316--34
Jan, 2561416--36
Dec, 2471515--37
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 13, 2025Sumant KulkarniCanaccord Genuity$265.00$138.0691.95%123.42%
Dec 09, 2024Michael YeeJefferies$180.00$157.7814.08%51.76%
Nov 15, 2024Brian SkorneyRobert W. Baird$300.00$162.8384.24%152.93%
Oct 31, 2024Jay OlsonOppenheimer$255.00$181.1840.74%114.99%
Oct 31, 2024Terence FlynnMorgan Stanley$204.00$181.1812.60%71.99%
Oct 30, 2024Christopher RaymondRaymond James$315.00$181.1873.86%165.58%
Oct 30, 2024Salveen RichterGoldman Sachs$290.00$181.1860.06%144.50%
Oct 17, 2024Evan SeigermanBMO Capital$230.00$188.1722.23%93.91%
Oct 03, 2024Ashwani VermaUBS$202.00$188.747.03%70.31%
Sep 23, 2024Laura ChicoWedbush$205.00$199.362.83%72.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 13, 2025Canaccord GenuityBuyBuyhold
Jan 02, 2025Piper SandlerOverweightNeutraldowngrade
Dec 09, 2024JefferiesBuyHolddowngrade
Nov 13, 2024CitigroupNeutralNeutralinitialise
Oct 31, 2024OppenheimerOutperformOutperformhold
Oct 31, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Oct 30, 2024Piper SandlerOverweightOverweighthold
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 17, 2024BMO CapitalOutperformOutperformhold
Oct 03, 2024UBSNeutralNeutralhold

Financial Forecast

EPS Forecast

$5 $12 $19 $26 $33 $40 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.86$10.44$20.97$8.02$11.20----
Avg Forecast$33.79$19.19$17.11$14.99$16.42$16.48$17.37$18.95$20.72
High Forecast$36.21$20.57$18.68$15.57$17.18$20.03$25.69$26.87$23.62
Low Forecast$31.69$18.00$15.76$14.74$16.13$14.45$13.83$15.13$18.61
Surprise %-26.43%-45.60%22.56%-46.50%-31.79%----

Revenue Forecast

$9B $10B $11B $12B $13B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.44B$10.98B$10.17B$9.84B$9.68B----
Avg Forecast$13.38B$10.87B$10.07B$9.93B$9.63B$9.43B$9.56B$9.92B$10.14B
High Forecast$14.12B$11.47B$10.78B$10.08B$9.74B$10.42B$9.57B$9.94B$11.23B
Low Forecast$12.74B$10.35B$9.46B$9.78B$9.55B$8.69B$9.56B$9.89B$9.35B
Surprise %0.48%1.01%1.00%-0.93%0.43%----

Net Income Forecast

$500M $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.00B$1.56B$3.05B$1.16B$1.63B----
Avg Forecast$3.27B$1.37B$1.82B$1.16B$2.42B$2.51B$2.37B$2.56B$3.02B
High Forecast$3.92B$1.64B$2.18B$1.39B$2.50B$2.92B$3.74B$3.91B$3.44B
Low Forecast$2.61B$1.09B$1.46B$928.88M$2.35B$2.10B$2.01B$2.20B$2.71B
Surprise %22.39%13.84%67.40%--32.69%----

BIIB Forecast FAQ

Is Biogen stock a buy?

Biogen stock has a consensus rating of Buy, based on 43 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 16 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Biogen is a favorable investment for most analysts.

What is Biogen's price target?

Biogen's price target, set by 43 Wall Street analysts, averages $240.4 over the next 12 months. The price target range spans from $160 at the low end to $315 at the high end, suggesting a potential 102.68% change from the previous closing price of $118.61.

How does Biogen stock forecast compare to its benchmarks?

Biogen's stock forecast shows a 102.68% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the drug manufacturers - general stocks industry (37.39%).

What is the breakdown of analyst ratings for Biogen over the past three months?

  • April 2025: 16.67% Strong Buy, 36.11% Buy, 47.22% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 36.11% Buy, 47.22% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 14.71% Strong Buy, 38.24% Buy, 47.06% Hold, 0% Sell, 0% Strong Sell.

What is Biogen’s EPS forecast?

Biogen's average annual EPS forecast for its fiscal year ending in December 2025 is $16.48, marking a 47.14% increase from the reported $11.2 in 2024. Estimates for the following years are $17.37 in 2026, $18.95 in 2027, and $20.72 in 2028.

What is Biogen’s revenue forecast?

Biogen's average annual revenue forecast for its fiscal year ending in December 2025 is $9.43B, reflecting a -2.54% decrease from the reported $9.68B in 2024. The forecast for 2026 is $9.56B, followed by $9.92B for 2027, and $10.14B for 2028.

What is Biogen’s net income forecast?

Biogen's net income forecast for the fiscal year ending in December 2025 stands at $2.51B, representing an 53.80% increase from the reported $1.63B in 2024. Projections indicate $2.37B in 2026, $2.56B in 2027, and $3.02B in 2028.